Skip to main content

Table 1 Clinical characteristics of patients in the primary cohort and validation cohort

From: Contrast-enhanced CT radiomics for predicting lymph node metastasis in pancreatic ductal adenocarcinoma: a pilot study

Characteristic

Primary Cohort

p

Validation Cohort

p

LN Metastasis (+)

LN Metastasis (−)

LN Metastasis (+)

LN Metastasis (−)

Age, mean ± SD, years

58.75 ± 10.07

56.95 ± 10.44

0.348

59.12 ± 9.69

57.75 ± 10.13

0.667

Gender, No. (%)

0.647

  

0.767

 Male

35 (67.3)

47 (71.2)

 

10 (58.8)

13 (54.2)

 

 Female

17 (33.7)

19 (28.8)

 

7 (41.2)

11 (45.8)

 

CEA level, No (%)

0.185

  

0.273

 Normal

41 (78.8)

58 (87.9)

 

10 (58.8)

18 (75.0)

 

 Abnormal

11 (21.2)

8 (12.1)

 

7 (41.2)

6 (25.0)

 

CA19–9 level, No (%)

0.116

  

0.529

 Normal

13 (25.0)

9 (13.6)

 

5 (29.4)

5 (20.8)

 

 Abnormal

39 (75.0)

57 (86.4)

 

12 (70.6)

19 (79.2)

 

TBIL level, No (%)

0.281

  

0.729

 Normal

19 (36.5)

18 (27.3)

 

4 (23.5)

8 (33.3)

 

 Abnormal

33 (63.5)

48 (72.7)

 

13 (76.5)

16 (66.7)

 

Lesion location, No (%)

0.595

  

0.262

 Head

43 (82.7)

52 (78.8)

 

15 (88.2)

17 (70.8)

 

 Body or tail

9 (17.3)

14 (21.2)

 

2 (11.8)

7 (29.2)

 

CT-reported LN status, No (%)

0.020*

  

0.019*

 LN- positive

34 (65.4)

29 (43.9)

 

12 (70.6)

8 (33.3)

 

 LN- negative

18 (34.6)

37 (56.1)

 

5 (29.4)

16 (66.7)

 

Pathological grade

0.008*

  

0.022*

 Well

8 (15.4)

22 (33.3)

 

3 (17.6)

11 (45.8)

 

 Moderately

17 (32.7)

24 (36.4)

 

6 (35.3)

9 (37.5)

 

 Poorly

27 (51.9)

20 (30.3)

 

8 (47.1)

4 (16.7)

 
  1. Abbreviations: CEA carcinoembryonic antigen, CA19–9 cancer antigen-19-9, TBIL total bilirubin, CT computed tomography, LN lymph node, SD standard deviation
  2. * highlights the p values that are smaller than 0.05